Firms
Theme

CAMT

Camtek Ltd · NASDAQ

News

12 latest

Zacks Investment Research

Camtek (CAMT) Increases Despite Market Slip: Here's What You Need to Know

Camtek stock rose 1.41% to $121.16 on October 23, 2026, outperforming a declining market. The company is expected to report earnings on November 4, 2026, with projected EPS of $0.98 (up 19.51% YoY) and quarterly revenue of $160.37 million (up 27.28% YoY). Camtek holds a Zacks Rank #2 (Buy) rating, though the stock has declined 17.67% over the past month and trades at a premium valuation with a Forward P/E of 32.97.

Zacks Investment Research

All You Need to Know About Camtek (CAMT) Rating Upgrade to Buy

Camtek (CAMT) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential near-term price appreciation driven by improved business fundamentals and institutional investor interest.

Zacks Investment Research

Why Camtek (CAMT) is Poised to Beat Earnings Estimates Again

Camtek (CAMT), a maker of automatic optical inspection systems, demonstrates a solid history of beating earnings estimates with an average surprise of 2.04% over the last two quarters. The company has a positive Earnings ESP of +2.55% combined with a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in the near term.

Zacks Investment Research

Camtek (CAMT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Camtek (CAMT) has declined 12.7% over the past week but formed a hammer chart pattern in its last trading session, suggesting a potential trend reversal. The stock is supported by positive fundamental indicators including upward earnings estimate revisions and a Zacks Rank #2 (Buy) rating, indicating strong analyst agreement on the company's improved prospects.

Zacks Investment Research

Camtek (CAMT) Declines More Than Market: Some Information for Investors

Camtek (CAMT) declined 3.29% on October 13, 2026, underperforming the broader market. Despite the daily decline, the stock has gained 10.3% over the past month.

Zacks Investment Research

Camtek (CAMT) Falls More Steeply Than Broader Market: What Investors Need to Know

Camtek stock declined 3.39% on October 12, 2026, underperforming the S&P 500's 0.06% loss. Despite the daily decline, the company maintains a Zacks Rank #2 (Buy) rating with positive earnings growth forecasts of 19.51% EPS growth and 26.27% revenue growth for the upcoming quarter. However, the stock trades at a premium valuation with a Forward P/E of 42.43 versus the industry average of 40.28.

Zacks Investment Research

Camtek (CAMT) Stock Declines While Market Improves: Some Information for Investors

Camtek (CAMT) declined 1.9% to $162.05 while the broader market gained, underperforming the S&P 500's 0.66% gain and Nasdaq's 1.05% rise. Despite strong year-to-date performance of 13.36%, the stock faces valuation concerns with a Forward P/E of 45.87 versus the industry average of 36.36. Upcoming earnings are projected to show 19.51% EPS growth and 26.27% revenue growth, though the stock currently holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

AEHR vs. CAMT: Which Semiconductor Equipment Stock Is the Better Bet?

Aehr Test Systems and Camtek are both positioned to benefit from AI and advanced packaging demand in semiconductors, but with different growth profiles. AEHR is entering a sharper growth phase with expected fiscal 2027 revenues of $130-$150 million (160%-200% growth) backed by a record $100.6 million backlog in AI-related burn-in solutions.

The Motley Fool

Camtek's 2026 Outlook: Strong Order Visibility Exceeds $600 Million Through End of 2027

Camtek, an Israeli semiconductor inspection equipment manufacturer, receives a Superscore of 82/100 from The Motley Fool's Hidden Gems database. The company benefits from strong demand for its Eagle G5 and Hawk platforms in AI infrastructure, with order visibility exceeding $600 million through end of 2027. However, elevated valuation multiples (P/E of 229) and heavy Asia-Pacific regional concentration (91% of revenue) present significant risks.

Mentions CAMT

Zacks Investment Research

Should You Buy, Sell or Hold AMAT Stock at a P/S Valuation of 9.59X?

Applied Materials (AMAT) has surged 111% year-to-date, trading at a premium P/S multiple of 9.59X versus the industry's 5.25X. Despite overvaluation concerns, the company is well-positioned to capitalize on AI-driven semiconductor demand, with strong growth in advanced packaging, DRAM/HBM technologies, and its AGS services business. Record AGS revenues of $1.78B (up 22% YoY) and plans to double manufacturing output by 2028 support a Zacks Rank #2 Buy recommendation.

Zacks Investment Research

ONTO Stock Up 126% in a Year: Is More Upside on the Horizon?

Onto Innovation (ONTO) has emerged as a key beneficiary of the AI semiconductor investment cycle, posting record revenue of $343.1M and a $1B+ backlog. The Dragonfly G5 product and advanced-packaging demand are driving an 80% growth outlook for 2026. However, after a 125.6% stock rally, valuation concerns persist with a forward P/E of 30.23X versus the industry average of 5.83X. The company faces risks from customer concentration, semiconductor cycles, and cost pressures.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $CAMT · 0 threads

Sign in to post on $CAMT

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev